Ness Therapeutics Inc. at Swiss Biotech Day 2026: A Strong Day One in Basel

The Setting

Swiss Biotech Day has grown into a premier global biotechnology conference for life sciences professionals, held annually at the Congress Center Basel and focused on fostering international collaboration and impactful partnerships. The embedded Global Village provides international delegations a platform to strengthen their ties with the Swiss biotech hub, promoting cross-border investments, public-private partnerships, R&D collaborations, and the exchange of best practices. It is a gathering where strategic conversations happen at the level of organizations, governments, and ecosystems.

Ness Therapeutics Inc. attended Swiss Biotech Day 2026 as part of a broader effort to extend the N001 program into international collaboration and to position the company within the global respiratory health and preparedness landscape.

European Government Engagement

Day one included substantive meetings with representatives from multiple European jurisdictions at the local government level, including France, Italy (Lombardy), Switzerland (the cantons of Neuchâtel and Vaud), and Germany (Berlin and Mainz). The conversations spanned several areas of mutual interest, with consistent themes: the value of early-stage biotech partnerships, the role of regional governments in supporting R&D expansion, and the opportunity to create high-quality life sciences employment through international collaboration.

There was strong interest across these conversations in extending Ness Therapeutics Inc.’s profile into European partnerships, with direct support from local government stakeholders for the kind of R&D and job creation that an advancing clinical-stage program can bring.

Nordic Interest in Defence Applications

A further thread in Day one's conversations came from collaborators in Nordic Europe. Norwegian representatives expressed specific interest in working with Ness Therapeutics Inc. on defence applications of N001, a dimension of the program that reflects the broader relevance of a deployable, host-directed prophylactic to high-readiness and frontline environments. The defence context aligns naturally with N001's core design principles: no pathogen-specific identification required, no clinical administration setting, and rapid scalability across populations and geographies.

Canada at Swiss Biotech Day

The day included a regulatory landscape discussion hosted by the Canadian team, one of several program elements organized around the Delegation of Canada's presence at the Global Village. The Global Village program also featured a session on leveraging regulatory collaboration to strengthen public-private innovation partnerships, providing important broader context for cross-jurisdictional development pathways.

A session featuring the Canadian Ambassador offered a compelling strategic frame for Canada's role as a trusted partner in health and innovation, underscoring the country's commitment to advancing life sciences internationally and its active engagement in the kind of cross-border collaboration that Swiss Biotech Day is designed to catalyze.

An International Reception to Close Day One

The day concluded with the international reception of the Global Village, a dedicated networking event where participants connected with international delegations in a relaxed and engaging setting. The Canadian contingent was strongly represented, and the evening was marked by substantive conversations across ecosystems. The energy of the reception reflected what was evident throughout the day: that the appetite for international collaboration is significant, and that the Global Village format creates genuine conditions for it to advance.

Day two continues.

N001 is currently in IND/CTA-enabling development, supported by funding from the Government of Canada and in partnership with the National Research Council of Canada. To follow the program's progress or explore investment and partnership opportunities, visit www.nesstherapeuticsinc.com/contact-us.